Minerva Biotechnologies

Exploring the Space between Stem Cells and Cancers

  • Stems Cells & Reagents
  • Functionalized Nanoparticles
  • Cancer Therapeutics

Show me more

Latest Products

News

  • Minerva Granted Worldwide License to Sendai Virus Technology for Stem Cell Generation

    Minerva Granted Worldwide License to Sendai Virus Technology for Stem Cell Generation

    WALTHAM, Massachusetts and Tsukuba, Ibaraki, Japan, August 27, 2015 Minerva Biotechnologies and ID Pharma Co., Ltd. (formerly DNAVEC) announced today that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary technology, for generating Induced Pluripotent Stem (iPS) cells. Sendai virus enables delivery […]

    Read More

  • Minerva Biotechnologies granted worldwide license to iPS technology

    Minerva Biotechnologies granted worldwide license to iPS technology

    WALTHAM, Massachusetts and KYOTO, Japan, August 4, 2015 Minerva Biotechnologies and iPS Academia Japan, Inc. announced today that they have signed an agreement granting Minerva worldwide rights to use and commercialize the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Professor Shinya Yamanaka, MD, Ph.D., who won the Nobel Prize for […]

    Read More

  • Research Scientist

    Research Scientist

    Research Scientist Minerva Biotechnologies has openings for PhD level scientists. Desirable backgrounds include Biochemistry with experience in cell culture, cloning, protein engineering, protein expression, purification and characterization and Cancer Biology with experience in cell culture, assay development, animal models, xenograft experiments and tumor biology.  Excellent opportunity for creative scientists.  Good work ethic is a must.  […]

    Read More